论文部分内容阅读
一、德国生物技术概况 德国是世界上最早进行生物技术研究的国家之一,特别是基因工程药物研究倍受重视。从80年代中起,德国生物技术研制费基本保持在每年10亿马克左右,近几年已猛增到每年23亿马克,仅德国政府的固定资助费每年就有3亿马克。德国的基因扩增技术和用于治疗的技术均走在世界前列。但由于伦理学、哲学和技术发展可控制性方面的考虑,德国政府对生物技术研究的审批程序一直比较严格,在一定程度上束缚了国内生物技术研究与开发的手脚,许多研究单位纷纷迁往国外。1993年以
First, the German biotechnology profile Germany is one of the first countries in the world to conduct biotechnology research, especially genetic engineering drug research has received much attention. From the middle of the 1980s, the German biotechnology research and development fees have remained at about 1 billion marks a year, and have soared to 2.3 billion marks a year in recent years. The fixed funding for the German government alone has 300 million marks per year. Germany’s gene amplification technology and the technologies used for its treatment have all taken the lead in the world. However, due to the consideration of the controllability of ethics, philosophy, and technology development, the German government’s examination and approval procedures for biotechnology research have been relatively strict. This has, to some extent, constrained the domestic research and development of biotechnology, and many research institutions have moved to foreign. In 1993